Cancer Vaccines Market

Global Cancer Vaccines Market Size

In 2024, the global cancer vaccines market was valued at USD 7.41 billion and it is expected to reach USD 31.11 billion by 2033 from USD 8.69 billion in 2025, growing at a CAGR of 17.28 % during the forecast period.

Vaccines were mostly used to prevent contagious diseases; they work by improving the immune response against pathogens. Similarly, cancer vaccines work by activating the immune system to attack cancer cells. Researchers developed therapeutic cancer vaccines to alleviate patients suffering from cancer. With the new technological advances, cancer vaccines have been developed as a new therapeutic way for cancer prevention and eradication. Broad ranges of therapeutics are currently available to combat cancer effectively, but they suffer from many glitches like low effectiveness and high specificity.

MARKET DRIVERS

The growing cancer patient population worldwide is propelling the cancer vaccines market growth primarily.

The influx of novel cancer vaccines into the market contributes to developing the global cancer vaccines market. The increase in demand for preventive vaccines among people due to increased awareness of infectious diseases catalyzes the growth of the cancer vaccines market. Also, governments and private organizations' increased investments to produce cancer vaccines and the development of alternative therapies due to a consistently rising account of cancer contribute to the growth of the global cancer vaccines market.Steadily increasing demand and adoption rates of therapeutic and preventive vaccines are expected to create lucrative growth opportunities for key market players in the global cancer vaccines market during the outlook period. Emerging economies of developing nations such as China and India are leading to the expansion and technological advancement of healthcare. They will likely offer many growth opportunities for the stakeholders operating in the worldwide cancer vaccines market. Increased focus of medical professionals on research and development of alternative therapies and treatments owing to the continually growing prevalence of cancer at an exponential rate is likely to provide lucrative growth opportunities for the key players functioning in the cancer vaccines market during the projection period.

MARKET RESTRAINTS

Stringent regulations and time-taking approval procedures of the FDA, restricting or delaying the launch of newly developed vaccines into the market, are a challenge to the key players and stakeholders, eventually limiting the growth of the cancer vaccines market. Side effects associated with the available therapies are challenging the development of the global cancer vaccine market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Type Insights

Based on the cancer type, the cervical cancer segment accounted for the largest share of the global cancer vaccines market share in 2022 and is expected to maintain its dominance over the forecast period, owing to an increase in the number of people infected with the human papillomavirus (HPV). Furthermore, the high prevalence of cervical cancer drives market development.On the other hand, the prostate cancer segment is projected to expand at the fastest rate of 14.10% CAGR during the forecast period owing to increased demand for Provenge (prostate cancer vaccine) and an increase in the number of prostate cancer vaccines in development.

By Vaccine Type Insights

Based on the vaccine type, the global demand for recombinant cancer vaccines dominated in 2022 and is projected to continue over the forecast period. This is because recombinant technology has been used to authorize several cancer vaccines, including Cervarix.

By End User Insights

Based on end-users, the cancer treatment centers segment contributes the largest share of revenues to the global cancer vaccines market. They are likely to continue the trend over the estimated period owing to the huge patient pool.

REGIONAL ANALYSIS

Geographically, North America is predicted to account for the largest share of the global cancer vaccines market due to increased cancer deaths. The government's escalating awareness about cancer by the government grows the patient’s treatment. High prevalence of cancer and the region's developed healthcare system, North America is projected to expand. According to the National Cancer Centre, cancers can be avoided using vaccines such as the Human papillomavirus (HPV) vaccine and the Hepatitis B virus vaccine (HBV). This vaccine is now recommended for men who have advanced types of cancer. Also, the FDA approved talimogene laherparepvec (T-VEC, or Imlygic), the first oncolytic virus therapy, in October 2015. This vaccine is used to treat metastatic melanoma that cannot be removed surgically.

The Asia Pacific is expected to show the highest growth due to increased healthcare expenditure in developing countries in this region. Increasing cancer vaccine acceptance, an increase in the number of cancer patients in emerging economies, the growth of the R&D industry, healthcare reforms, and technological advances in cancer vaccines are providing lucrative opportunities for key players operating in the cancer vaccines market in the Asia Pacific. Furthermore, increased investment from the public and private sectors to develop novel cancer vaccines, an increased number of hospitals and diagnostic centers with advanced medical facilities, and a large population base contribute to the market's growth. Besides that, leading manufacturers' increased emphasis on expanding their geographical presence in developing Asia-Pacific countries to capture a high market share is expected to fuel the region's cancer vaccines market growth.

KEY MARKET PLAYERS

Companies that are playing a leading role in the global cancer vaccines market profiled in the report are Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech.

RECENT HAPPENINGS IN THE MARKET

• In recent studies, researchers have found that the most common viruses responsible for cancer are HPV, Epstein - Barr virus, and human Herpesvirus 6B, Hepatitis B virus. The researchers suggest that cancer prevention is better than cure as they found many infections in tumors. According to the researchers, cancer can be battled in a much more effective way if the cancer's root cause is known. The researchers claimed that a novel set of cancer vaccines (such as the HPV vaccine) could be developed by altering the DNA of various viruses by analyzing the link between infections and cancer.

• In recent studies carried out by scientists at a cancer research institute in London, scientists have found that immunotherapy can be improved by creating an influential vaccine by supercharging the rate of mutation in cancer cells. The technique will enable them to develop vaccines for various types of cancers.

• The research and development team of EPFL confirmed that they are currently working on an alternative personalized cancer vaccine to integrate the polycondensation technique. The vaccine is delivered automatically and activates the immune cells at the desired location with high accuracy.

MARKET SEGMENTATION

This research report on the global cancer vaccines market has been segmented and sub-segmented based on the cancer type, vaccine type, end-users, and region.

By Cancer Type

• Prostate
• Cervical
• Colorectal
• Throat
• Others

By Vaccine Type

• Protein
• Peptide-based
• Tumor cell
• Dendritic cell
• Genetic vaccines
• Others

By End User

• Cancer Treatment Centres
• Research Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa